Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

The ways in which pharmaceutical companies market their drugs directly to consumers in the U.S. could face quite the ...

The pharma industry’s standing among the U.S. public has reached a new steady state after the rise and fall it underwent as ...

The OHG leadership shake-up comes amid a larger period of transition for Omnicom. In early December, the company laid out its ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City ...

While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the first medicine the Carlsbad, ...

Shortly after unveiling a $400 million upgrade at its campus in Hillerød, Denmark, Novo Nordisk is reinforcing its commitment ...

Christmas seems to have come early for Klick Health, with a slew of new leaders arriving under the life sciences marketing ...